Kevin Sabet advises on the FDA's drug policy process, which is being reported on in public hearings.
1 report, 1 independent
Updated Sep 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Kevin Sabet advises on the FDA's drug policy process, which is being reported on in public hearings.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Kevin Sabet
American scholar, commentator, and adviser
-
Fierce
Nothing else this week.
Related events
- Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.
- The FDA is currently reviewing the supplemental New Drug Application (sNDA) for Arikayce's full product approval.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- The FDA is reviewing drug data and company resubmissions, while also overseeing the functions of the U.S. Department of Health and Human Services.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.